List view / Grid view



FDA grants Breakthrough designation to ibrutinib in cGVHD

1 July 2016 | By Victoria White, Digital Content Producer

The US Food and Drug Administration (FDA) has granted a fourth Breakthrough Therapy Designation for ibrutinib (Imbruvica) as monotherapy for the treatment of patients with chronic graft-versus-host-disease (cGVHD) after failure of one or more lines of systemic therapy.